Systematic surveillance of patient-reported symptoms of viral respiratory tract infectious Syndromes in diverse populations

BMC Health Services Research

Research

Musu Sesay¹  Sandra A. Amouzou¹  Alexander F. Hudgins¹  Lee Cromwell¹  Jennifer C. Gander¹  Marni Segall¹  John D. Powers²  Brian C. Martinson³  Anjali R. Truitt³  Prasanthi Kodthala³  Ella Chrenka³  Douglas Roblin⁴  Adrienne N. Deneal⁴  Thomas Whiting⁴ 

[1] Center for Research and Evaluation, Kaiser Permanente Georgia, Atlanta, GA, USA;Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA;HealthPartners Institute, Bloomington, MN, USA;Mid-Atlantic Permanente Research Institute, Kaiser Permanente Mid-Atlantic States, Rockville, MD, USA;

关键词: Patient-reported outcome measures;    COVID-19;    Influenza-like illness;    Patient-centered care;   

DOI  :  10.1186/s12913-022-08991-3

 received in 2022-04-19, accepted in 2022-12-20,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundPatient reported outcome measures (PROM) can improve patient care and be crucial for symptom tracking especially during disease outbreaks. FLU-PRO Plus is a validated PROM used to track viral respiratory symptoms. Our study aimed to evaluate the feasibility of using FLU-PRO© Plus, to track symptoms across three healthcare systems.MethodsThe prospective, longitudinal study recruited adults between February-May 2021 from HealthPartners Institute (HP), Kaiser Permanente Georgia (KPGA), and Kaiser Permanente Mid-Atlantic States (KPMAS). Adult members were eligible if they had a positive lab or diagnosis for either COVID-19 or influenza-like illness (ILI) or exhibited 2 + viral respiratory symptoms. Descriptive statistics were calculated to describe the patient characteristics for participants that were eligible for FLU-PRO Plus, successfully contacted, attempted to log in to the FLU-PRO Plus website, and participants who completed FLU-PRO Plus Day 1. Bivariable and multivariable logistic regression using PROC GLIMMIXX investigated the patient characteristics associated with (1) successful contact and (2) FLU-PRO Plus Day 1 completion.ResultsWe identified a total of 15,650 eligible participants during the enrollment period: 9,582 from HP, 1,740 from KPGA, and 4,328 from KPMAS. Among the total of 409 eligible adults who attempted to participate in FLU-PRO Plus, 317 completed FLU-PRO Plus Day 1. Among the 317 individuals that completed FLU-PRO Plus Day 1, 205 (67.5%) were diagnosed with COVID-19; 112 adults diagnosed with COVID-19 completed FLU-PRO Plus Day 14. Among adults successfully contacted, adults aged 35–64 (OR = 1.40, 95% CI 1.05, 1.87), females (OR = 1.77, 95% CI 1.38, 2.27), and adults diagnosed with COVID-19 (OR = 1.66, 95% CI 1.27, 2.17) had higher odds of completing FLU-PRO Plus Day 1; Asian adults (OR = 0.38, 95% CI 0.19, 0.76) and Black and African American adults (OR = 0.33, 95% CI 0.19, 0.76) had lower odds compared to White adults.ConclusionOur study reports on the feasibility of patients across three integrated healthcare systems utilizing FLU-PRO Plus to monitor their respiratory symptoms. Patient reported outcome measures (PROM) can improve patient care, quality of life, and reduce the strain of limited resources on healthcare systems. Future FLU-PRO Plus studies should develop an implementation strategy to fully integrate FLU-PRO Plus within clinical care and patient management.

【 授权许可】

CC BY   
© The Author(s) 2022

【 图 表 】

12888_2022_4392_Article_IEq2.gif

12982_2022_119_Article_IEq188.gif

12982_2022_119_Article_IEq42.gif